BPC-157 vs TB-500: A Research Comparison
BPC-157 and TB-500 are two of the most frequently studied peptides in tissue-repair research, and they are often mentioned together. They are, however, distinct compounds with different origins and different research profiles.
This guide compares the two on origin, structure and research focus — strictly in the context of laboratory research. Both compounds are supplied for in vitro and research use only and are not for human or veterinary use.
On this page
Overview
Both BPC-157 and TB-500 appear widely in connective-tissue, cell-migration and wound-healing research models. They are different molecules: BPC-157 is a synthetic pentadecapeptide derived from a gastric protein, while TB-500 is a synthetic peptide based on the actin-binding protein Thymosin Beta-4.
What BPC-157 is
BPC-157 (Body Protection Compound-157) is a stable fifteen-amino-acid sequence derived from a protective protein found in gastric juice. Its notable stability in aqueous and acidic conditions has made it a frequent subject of in vitro and pre-clinical study, particularly in tendon, ligament and gut-tissue research models. Full product detail is on the BPC-157 page.
What TB-500 is
TB-500 is a synthetic peptide based on the actin-binding region of Thymosin Beta-4, a naturally occurring protein involved in cytoskeletal dynamics. Its principal research interest is its interaction with actin, which places it in cell-migration and tissue-organization research. Full product detail is on the TB-500 page.
Key differences
Origin
BPC-157 is derived from a sequence found in gastric juice. TB-500 is based on Thymosin Beta-4, a widely expressed actin-binding protein. The two have entirely separate biological backgrounds.
Structure
BPC-157 is a defined fifteen-residue pentadecapeptide. TB-500 is a larger peptide based on the Thymosin Beta-4 sequence — researchers should confirm exact sequence and molecular weight against the Certificate of Analysis for their lot.
Research focus
BPC-157 features heavily in tendon, ligament and gastrointestinal-tissue research. TB-500 is most associated with actin regulation, cell migration and angiogenesis models. The areas overlap in wound-healing research, which is part of why the two are discussed together.
Why they are studied together
Because both compounds appear in wound-healing and connective-tissue research, study designs sometimes examine them in parallel or in combination. Acting through different mechanisms, they are a natural pairing for comparative research models — though any such use is strictly within an in vitro or laboratory research context.
Documentation matters for both
For either compound, the Certificate of Analysis is what makes a research result trustworthy. Purity and identity should be verified per lot — see our guides on reading a CoA and peptide purity. Every PX1 Labs batch of both peptides is verified at 99%+ identity purity with a lot-specific Certificate of Analysis included.
Frequently asked questions
What is the main difference between BPC-157 and TB-500?
They are different molecules with different origins. BPC-157 is a pentadecapeptide derived from a gastric protein; TB-500 is a synthetic peptide based on the actin-binding protein Thymosin Beta-4. Their research models overlap in tissue repair, which is why they are often compared.
Can BPC-157 and TB-500 be studied together?
They are sometimes examined in parallel in tissue-repair research because they act through different mechanisms. Any such use is strictly within an in vitro or laboratory research context — both are for research use only.
Are BPC-157 and TB-500 for human use?
No. Both are supplied strictly for laboratory and in vitro research. They are not approved for human or veterinary use, diagnosis, or treatment.